Weight-Loss drug may change breast cancer risk markers
NCT ID NCT06485089
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether tirzepatide, a weight-loss drug, could change certain markers in the blood, breast tissue, and mammograms that are linked to breast cancer risk. It included 25 women with obesity and other breast cancer risk factors. The goal was to see if the drug might lower their risk, but the main focus was on whether the study design itself was practical.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER RISK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
University of Kansas Medical Center Breast Cancer Prevention Center
Westwood, Kansas, 66208, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Timing your meals or halving your rice: a new trial tests simple diet hacks for weight loss and blood sugar control
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Can a new drug boost Semaglutide's power against diabetes and obesity?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?
- A daily pill for obesity? zenagamtide faces its biggest test yet.
- Dance and walking may boost heart health in obesity — a trial puts it to the test